Human Genome Epidemiology Literature Finder
|
Records 1 - 19 (of 19 Records) |
| Query Trace: Anemia and IL28B[original query] |
|---|
| IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. The Journal of infectious diseases 2011 Jul 204 (1): 84-93. Chayama Kazuaki, Hayes C Nelson, Abe Hiromi, Miki Daiki, Ochi Hidenori, Karino Yoshiyasu, Toyota Joji, Nakamura Yusuke, Kamatani Naoyuki, Sezaki Hitomi, Kobayashi Mariko, Akuta Norio, Suzuki Fumitaka, Kumada Hiromit |
| Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. Journal of medical virology 2011 Jun 83 (6): 1048-57. Azakami Takahiro, Hayes C Nelson, Sezaki Hitomi, Kobayashi Mariko, Akuta Norio, Suzuki Fumitaka, Kumada Hiromitsu, Abe Hiromi, Miki Daiki, Tsuge Masataka, Imamura Michio, Kawakami Yoshiiku, Takahashi Shoichi, Ochi Hidenori, Nakamura Yusuke, Kamatani Naoyuki, Chayama Kazua |
| Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin. Viruses 2012 Aug 4 (8): 1264-78. Miyamura Tatsuo, Kanda Tatsuo, Nakamoto Shingo, Wu Shuang, Jiang Xia, Arai Makoto, Fujiwara Keiichi, Imazeki Fumio, Yokosuka Osa |
| Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1. Journal of medical virology 2012 Aug 84 (8): 1208-16. Amanzada Ahmad, Schneider Simon, Moriconi Federico, Lindhorst Alexander, Suermann Thomas, van Thiel David H, Mihm Sabine, Ramadori Giulia |
| Efficacy of reduction therapy of natural human ß-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load. Hepatology research : the official journal of the Japan Society of Hepatology 2012 Oct 42 (10): 949-57. Arase Yasuji, Kawamura Yusuke, Suzuki Yoshiyuki, Suzuki Fumitaka, Akuta Norio, Matsumoto Naoki, Seko Yuya, Sezaki Hitomi, Kobayashi Masahiro, Hosaka Tetsuya, Hirakawa Miharu, Saito Satoshi, Ikeda Kenji, Kobayashi Mariko, Kumada Hiromit |
| Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants. PloS one 2012 7 (11): e47725. Vidal Francesc, López-Dupla Miguel, Laguno Montserrat, Veloso Sergi, Mallolas Josep, Murillas Javier, Cifuentes Carmen, Gallart Lluis, Auguet Teresa, Sampériz Gloria, Payeras Antoni, Hernandez Pilar, Arnedo Mireia, Gatell Josep Ma, Richart Cristób |
| Effect of laparoscopic splenectomy in patients with Hepatitis C and cirrhosis carrying IL28B minor genotype. BMC gastroenterology 2012 12 158. Motomura Takashi, Shirabe Ken, Furusyo Norihiro, Yoshizumi Tomoharu, Ikegami Toru, Soejima Yuji, Akahoshi Tomohiko, Tomikawa Morimasa, Fukuhara Takasuke, Hayashi Jun, Maehara Yoshihi |
| A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C. Journal of medical virology 2013 Oct 85 (10): 1746-53. Hara Tasuku, Akuta Norio, Suzuki Fumitaka, Sezaki Hitomi, Suzuki Yoshiyuki, Hosaka Tetsuya, Kobayashi Masahiro, Kobayashi Mariko, Saitoh Satoshi, Kumada Hiromit |
| Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients. Journal of hepatology 2013 Nov 59 (5): 964-71. Scherzer Thomas-Matthias, Stättermayer Albert Friedrich, Stauber Rudolf, Maieron Andreas, Strasser Michael, Laferl Hermann, Schwarzer Remy, Datz Christian, Rutter Karoline, Beinhardt Sandra, Steindl-Munda Petra, Hofer Harald, Ferenci Pet |
| Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C. Journal of medical virology 2013 Jan . Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Matsuura K, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Tokunaga K, Mizokami M, Izumi N |
| Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology (Baltimore, Md.) 2014 Jun 59 (6): 2131-9. Rembeck Karolina, Waldenström Jesper, Hellstrand Kristoffer, Nilsson Staffan, Nyström Kristina, Martner Anna, Lindh Magnus, Norkrans Gunnar, Westin Johan, Pedersen Court, Färkkilä Martti, Langeland Nina, Buhl Mads Rauning, Mørch Kristine, Christensen Peer Brehm, Lagging Mart |
| Role of ITPA and IL28B variants in the management of chronic hepatitis C treatment. Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 2015 Jun 23 (2): 134-9. Zampino Rosa, Alessio Loredana, Marrone Aldo, Stanzione Maria, Boemio Adriana, Grandone Anna, Minichini Carmine, Pisaturo Mariantonietta, Starace Mario, Adinolfi Luigi Elio, Sagnelli Evangelista, Coppola Nico |
| [Combined telaprevir plus ribavirin and pegylated interferon therapy for patients with chronic hepatitis C]. Nihon rinsho. Japanese journal of clinical medicine 2015 Feb 73 (2): 259-65. Mochida Satos |
| Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study. PloS one 2015 10 (12): e0145105. About Frédégonde, Oudot-Mellakh Tiphaine, Niay Jonathan, Rabiéga Pascaline, Pedergnana Vincent, Duffy Darragh, Sultanik Philippe, Cagnot Carole, Carrat Fabrice, Marcellin Patrick, Zoulim Fabien, Larrey Dominique, Hézode Christophe, Fontaine Hélène, Bronowicki Jean-Pierre, Pol Stanislas, Albert Matthew L, Theodorou Ioannis, Cobat Aurélie, Abel Laurent, |
| ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. PloS one 0 10 (12): e0144004. Asselah Tarik, Zeuzem Stefan, Soriano Vicente, Bronowicki Jean-Pierre, Lohse Ansgar W, Müllhaupt Beat, Schuchmann Marcus, Bourlière Marc, Buti Maria, Roberts Stuart K, Gane Edward J, Stern Jerry O, Voss Florian, Baum Patrick, Gallivan John-Paul, Böcher Wulf O, Mensa Federico |
| Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection. PloS one 2016 11 (7): e0158512. Kuntzen Thomas, Kuhn Sereina, Kuntzen Daniela, Seifert Burkhardt, Müllhaupt Beat, Geier Andre |
| Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. World journal of gastroenterology 2016 Mar 22 (12): 3418-31. Jacobson Ira, Zeuzem Stefan, Flisiak Robert, Knysz Brygida, Lueth Stefan, Zarebska-Michaluk Dorota, Janczewska Ewa, Ferenci Peter, Diago Moises, Zignego Anna Linda, Safadi Rifaat, Baruch Yaacov, Abdurakhmanov Dzhamal, Shafran Stephen, Thabut Dominique, Bruck Rafael, Gadano Adrian, Thompson Alexander James, Kopit Justin, McPhee Fiona, Michener Tracy, Hughes Eric A, Yin Philip D, Noviello Stephan |
| Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy. Journal of medical virology 2016 Mar . Tahata Yuki, Hiramatsu Naoki, Oze Tsugiko, Urabe Ayako, Morishita Naoki, Yamada Ryoko, Yakushijin Takayuki, Hosui Atsushi, Oshita Masahide, Kaneko Akira, Hagiwara Hideki, Mita Eiji, Ito Toshifumi, Yamada Yukinori, Inada Masami, Katayama Kazuhiro, Tamura Shinji, Imai Yasuharu, Hikita Hayato, Sakamori Ryotaro, Yoshida Yuichi, Tatsumi Tomohide, Hayashi Norio, Takehara Tets |
| Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens. PloS one 2018 13 (5): e0198296. Vasanthakumar Aparna, Davis Justin W, Abunimeh Manal, Söderholm Jonas, Zha Jiuhong, Dumas Emily O, Cohen Daniel E, Waring Jeffrey F, Lagging Mart |
- Page last reviewed:Feb 1, 2024
- Content source: